4503.T
Astellas Pharma Inc.$2,169.50
Jun 02, 2026
Revenue · FY
$2.14T
Net income
$291.54B
FY 2026
EPS · diluted
$162.22
EBITDA
$614.29B
Explain this page
Arphra AIPlain-English read on Astellas Pharma Inc.’s valuationPro
Valuation & DCF
Our full DCF model and fair-value breakdown is included with Pro.
- Multi-scenario DCF with editable assumptions
- Fair value vs market price
- Reverse-DCF implied expectations